MEREO BIOPHARMA GROUP PLC (MREO) Current Ratio
- Current ratio · latest quarter: Value 5.88×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.88× | Current assets / current liabilities. $33.40M ÷ $5.68M ≈ 5.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 33.40M USD | Assets, Current |
| Current obligations | 5.68M USD | Liabilities, Current |
| Cash and equivalents | 30.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.12M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.40M | $5.68M | $30.12M | (m) | (m) | (m) | $1.12M | (m) | 5.88× |
| 2026-03-31 | $40.03M | $6.18M | $36.22M | (m) | (m) | (m) | $3.23M | (m) | 6.48× |
| 2025-12-31 | $45.02M | $4.30M | $40.99M | (m) | (m) | (m) | $1.33M | (m) | 10.46× |
| 2025-09-30 | $52.41M | $6.02M | $48.70M | (m) | (m) | (m) | $879.00K | (m) | 8.71× |
| 2025-06-30 | $61.42M | $7.56M | $56.13M | (m) | (m) | (m) | $1.14M | (m) | 8.13× |
| 2025-03-31 | $66.90M | $7.50M | $62.48M | (m) | (m) | (m) | $2.92M | (m) | 8.92× |
| 2024-12-31 | $74.76M | $13.85M | $69.80M | (m) | (m) | (m) | $2.44M | (m) | 5.40× |
| 2024-09-30 | $86.72M | $14.21M | $80.52M | (m) | (m) | (m) | $1.75M | (m) | 6.10× |
| 2024-06-30 | $93.94M | $15.47M | $87.43M | (m) | (m) | (m) | $2.70M | (m) | 6.07× |
| 2024-03-31 | $53.50M | $11.00M | $48.66M | (m) | (m) | (m) | $2.46M | (m) | 4.86× |
| 2023-12-31 | $63.76M | $9.49M | $57.42M | (m) | (m) | (m) | $2.35M | (m) | 6.72× |
| 2022-12-31 | $75.20M | $24.38M | $68.18M | (m) | (m) | (m) | $3.49M | (m) | 3.09× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |